Rastogi Kartick, Jain Sandeep, Bhatnagar Aseem Rai, Bhaskar Sandeep, Gupta Shivani, Sharma Neeraj
Department of Radiotherapy, SMS Medical College and Attached Group of Hospitals, Jaipur, Rajasthan, India.
Asia Pac J Oncol Nurs. 2018 Jan-Mar;5(1):107-113. doi: 10.4103/apjon.apjon_46_17.
The aim of this study was to compare toxicity and locoregional control of short duration hypofractionated (HF) radiotherapy (RT) with conventional RT in breast cancer patients.
A total of 100 postmastectomy breast cancer patients were randomized for adjuvant RT in control group (comprising fifty patients who received the standard conventional dose of 50 Gy in 25 fractions with 2 Gy per fraction) and study group (comprising fifty patients who received HF RT with dose of 42.72 Gy in 16 fractions with 2.67 Gy per fraction). All patients were treated on linear accelerator with 3-dimensional conformal RT technique. Outcome was analyzed in terms of toxicity, tolerability, and locoregional control.
In the present study, at a median follow-up of 20 months, almost similar results were seen in both the groups in terms of toxicity, tolerability, and locoregional control. Adjuvant postmastectomy HF RT was found to be well tolerated with mild-to-moderate side effects that neither reached statistical significance nor warranted any treatment interruption/hospitalization.
HF postmastectomy RT is comparable to conventional RT without evidence of higher adverse effects or inferior locoregional tumor control and has an added advantage of increased compliance because of short duration; hence, it can help in accommodating more breast cancer patients in a calendar year, ultimately resulting in decreased waiting list, increased turnover, and reduced cost of treatment.
本研究旨在比较短疗程大分割(HF)放疗(RT)与传统放疗对乳腺癌患者的毒性和局部区域控制情况。
总共100例乳房切除术后的乳腺癌患者被随机分为对照组(50例患者接受标准传统剂量放疗,即25次分割,每次2 Gy,总剂量50 Gy)和研究组(50例患者接受大分割放疗,16次分割,每次2.67 Gy,总剂量42.72 Gy)。所有患者均采用直线加速器和三维适形放疗技术进行治疗。从毒性、耐受性和局部区域控制方面对结果进行分析。
在本研究中,中位随访20个月时,两组在毒性、耐受性和局部区域控制方面的结果几乎相似。乳房切除术后辅助性大分割放疗耐受性良好,副作用为轻至中度,既未达到统计学显著性,也无需中断任何治疗或住院治疗。
乳房切除术后大分割放疗与传统放疗效果相当,没有证据表明其不良反应更高或局部区域肿瘤控制效果更差,且因疗程短而具有依从性增加的额外优势;因此,它有助于在一个日历年中接纳更多乳腺癌患者,最终减少等待名单、提高周转率并降低治疗成本。